Posted by Michael Wonder on 17 Jan 2023
China NMPA approves Bio-Thera Solutions’ BAT1806, a biosimilar to Actemra (tocilizumab)
16 January 2023 - World’s first approved biosimilar to Actemra.
Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra (tocilizumab), in China.
BAT1806 is the first tocilizumab biosimilar approved by the NMPA or any other regulatory agency around the world and has been approved for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome.
